AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03045328
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
Trial: NCT03045328
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
Trial: NCT00536601
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02502734
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Trial: NCT02502734
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol will be provided as a inhaler.
Trial: NCT02253602
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: maximum rate of administration 1 ml/sec
Trial: NCT03563846
Drug: RP-G28
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP-G28 is a purified galacto-oligosaccharide (GOS) product
Trial: NCT00536601
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00536601
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00536601
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00536601
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00536601
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02070692
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 day course of tamoxifen during an episode of irregular vaginal bleeding
Trial: NCT01713426
Drug: Qutenza
RxNorm normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cutaneous patch
Trial: NCT01713426
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral capsule
Trial: NCT02569723
Drug: Carbon C 14 Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT02569723
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04805307
Drug: CMG901
RxNorm normalized name: CMG901
DrugBank: CMG901 (DB18619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until confirmed Progressive Disease(PD), unacceptable toxicity, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first.
Trial: NCT00355472
Drug: KW-0761
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration at 4 escalating dose levels.
Trial: NCT04487743
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Trial: NCT02560584
Drug: Hexaminolevulinate hydrochloride
RxNorm normalized name: Hexaminolevulinate hydrochloride
DrugBank: Hexaminolevulinate (DB06261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation in bladder
Trial: NCT01408095
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01638650
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg bid orally, Days 1-14
Trial: NCT01638650
Drug: saquinavir [Invirase]
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
Trial: NCT02865395
Drug: Belladonna and Opium Suppository
RxNorm normalized name: belladonna alkaloids / opium Rectal Suppository
DrugBank: Opium (DB11130)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04392557
Drug: Metformin / alogliptin Oral Product
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
Trial: NCT04392557
Drug: Metformin / Pioglitazone Pill
RxNorm normalized name: metformin / pioglitazone Pill
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (850 mg/15 mg every 12 hours) for 12 months
Trial: NCT03418168
Drug: Molidustat (BAY85-3934)
RxNorm normalized name: Molidustat
DrugBank: Molidustat (DB15642)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Trial: NCT02266745
Drug: PT-112 Injection
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04131231
Drug: recombinant human interleukin-2(rhIL-2)
RxNorm normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50ml, intrapleural infusion, day5,8,11
Trial: NCT03138681
Drug: Phosphocreatine
RxNorm normalized name: Phosphocreatine
DrugBank: Phosphocreatine (DB13191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphocreatine (1g) is given intravenously twice a day for 14 days
Trial: NCT02689999
Drug: Dexrabeprazole 10 mg Enteric-Coated Tablets
RxNorm normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01534637
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01534637
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04471402
Drug: Precedex
RxNorm normalized name: Precedex
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal Precedex 3mcg/kg
Trial: NCT00720226
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg daily
Trial: NCT01497626
Drug: Lapatinib and bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts.
Trial: NCT00789763
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2/one per week, i.v., during 5 weeks.
Trial: NCT00789763
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-800 mg/day p.o. during 5 weeks
Trial: NCT04038086
Drug: effect of insulin on peptide transport
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
Trial: NCT01923584
Drug: EPI-743 400mg
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01923584
Drug: EPI-743 200mg
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00065455
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03116321
Drug: Eslicarbazepine acetate (ESL)
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet of 800 mg and 200 mg of ESL
Trial: NCT01020799
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg, oral, once daily (QD)
Trial: NCT01606852
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
Trial: NCT00662259
Drug: Alprazolam (Xanax)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
Trial: NCT03597867
Drug: Nevanac
RxNorm normalized name: Nevanac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing of drug 3 days prior to surgery
Trial: NCT00568074
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02245867
Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
Trial: NCT01602016
Drug: Folinic Acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
Trial: NCT02595008
Drug: DSXS
RxNorm normalized name: Dexamethasone sodium succinate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active treatment
Trial: NCT03507413
Drug: Metformin Glucophage 500mg (IR) tablets M90
RxNorm normalized name: metformin hydrochloride 500 MG [Glucophage]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
Trial: NCT03597867
Drug: Yellox
RxNorm normalized name: yellow OB
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing of drug 3 days prior to surgery
Trial: NCT02694874
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
Trial: NCT01824901
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04120831
Drug: Abatacept Injection
RxNorm normalized name: abatacept Injection
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug
Trial: NCT00004443
Drug: NTBC
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04544098
Drug: 177Lu-DOTATATE
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
Trial: NCT01548482
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00998972
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg intravenous before and 2 hours after cerebral arteriography
Trial: NCT01626560
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daptomycin 4-6mg/kg qd 10 - 14 days
Trial: NCT01626560
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 1g q12h 10 - 14 days
Trial: NCT00759954
Drug: morphine sulfate sustained-release capsules
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 200 mg, single-dose capsule
Trial: NCT00403182
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00759954
Drug: KADIAN (morphine sulfate sustained-release) capsules
RxNorm normalized name: morphine sulfate Extended Release Oral Capsule [Kadian]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 100 mg, single-dose capsule
Trial: NCT01764243
Drug: MT-4666
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose, high dose
Trial: NCT02551731
Drug: Cannabidiol Oral Solution
RxNorm normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 or 40 mg/kg/day BID
Trial: NCT00165230
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00165230
Drug: Temodar
RxNorm normalized name: Temodar
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01523587
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
Trial: NCT01523587
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erlotinib taken once daily
Trial: NCT00155233
Drug: Nalbuphine and morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02631876
Drug: Mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
Trial: NCT02631876
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered per dose and schedule specified in the arm.
Trial: NCT02631876
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan will be administered per dose and schedule specified in the arm.
Trial: NCT02172482
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide18 micrograms (capsule with powder for inhalation)
Trial: NCT04232241
Drug: Allogeneic Stem Cell Transplantation
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic Stem Cell Transplantation
Trial: NCT00489281
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
Trial: NCT00489281
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
Trial: NCT00489281
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
Trial: NCT00489281
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given at 500 mg PO twice daily from Day -6 to Day +365.
Trial: NCT00302302
Drug: L-arabinose
RxNorm normalized name: L-Arabinose
DrugBank: L-Arabinose (DB16873)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02714231
Drug: hyoscine butyl bromide (buscopan)
RxNorm normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
Trial: NCT02780427
Drug: intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).
Trial: NCT00521274
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
Trial: NCT00724373
Drug: Ribavirin (SCH 18908)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
Trial: NCT02924376
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
Trial: NCT00536484
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
Trial: NCT02529202
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine infusion
Trial: NCT01334684
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin, pills, 850 mg three times a day for three months
Trial: NCT01166555
Drug: PF-04236921
RxNorm normalized name: HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY (PF-04236921)
DrugBank: Human anti-il-6 monoclonal antibody (pf-04236921) (DB19307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous dose
Trial: NCT01506908
Drug: oral nicotine
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral nicotine replacement product
Trial: NCT02980250
Drug: over dose
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Trial: NCT02980250
Drug: Glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
Trial: NCT02510014
Drug: SUBOXONE sublingual film
RxNorm normalized name: buprenorphine / naloxone Sublingual Film [Suboxone]
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.